A systematic approach for the identification of novel, serologically reactive recombinant Varicella-Zoster Virus (VZV) antigens.

Virology Journal
Maria G Vizoso PintoArmin Baiker

Abstract

Varicella-Zoster virus causes chickenpox upon primary infection and shingles after reactivation. Currently available serological tests to detect VZV-specific antibodies are exclusively based on antigens derived from VZV-infected cells. We present a systematic approach for the identification of novel, serologically reactive VZV antigens. Therefore, all VZV open reading frames were cloned into a bacterial expression vector and checked for small scale recombinant protein expression. Serum profiling experiments using purified VZV proteins and clinically defined sera in a microarray revealed 5 putative antigens (ORFs 1, 4, 14, 49, and 68). These were rearranged in line format and validated with pre-characterized sera. The line assay confirmed the seroreactivity of the identified antigens and revealed its suitability for VZV serodiagnostics comparable to commercially available VZV-ELISA. Recombinant ORF68 (gE) proved to be an antigen for high-confidence determination of VZV serostatus. Furthermore, our data suggest that a serological differentiation between chickenpox and herpes zoster may be possible by analysis of the IgM-portfolio against individual viral antigens.

References

Nov 23, 1990·Journal of Chromatography·E SoutschekM Motz
Dec 1, 1974·The Journal of Infectious Diseases·V WilliamsP A Brunell
Jul 1, 1996·Clinical Microbiology Reviews·A M Arvin
May 18, 1999·Analytical Biochemistry·A LuekingG Walter
Dec 1, 2000·The Pediatric Infectious Disease Journal·P LaRussaA A Gershon
Mar 29, 2001·The New England Journal of Medicine·A M Arvin
Sep 29, 2001·Journal of Clinical Pathology·J Breuer
Apr 10, 2003·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Amy BehrmanBarbara Watson
Aug 1, 1994·Clinical and Diagnostic Virology·A A GershonS Steinberg
Jan 18, 2005·Clinical Microbiology Reviews·Sophie Hambleton, Anne A Gershon
May 14, 2005·Journal of Virology·Jeffrey I CohenElena A Prikhod'ko
Aug 9, 2005·Clinical and Diagnostic Laboratory Immunology·Klaus-Ingmar PfrepperErwin Soutschek
Dec 1, 2005·Journal of Veterinary Medicine. B, Infectious Diseases and Veterinary Public Health·K-I PfrepperM Motz
Mar 16, 2007·The New England Journal of Medicine·Sandra S ChavesJane F Seward
May 30, 2009·Journal of Virological Methods·Anne J JääskeläinenHeli Piiparinen

❮ Previous
Next ❯

Citations

Aug 7, 2012·The Pediatric Infectious Disease Journal·Andreas C W JenkeMaria G Vizoso-Pinto
Jan 25, 2012·Virology Journal·Andreas OstermanArmin Baiker
Jan 1, 2010·International Journal of Molecular Sciences·Mohan Natesan, Robert G Ulrich
Nov 20, 2013·Scientific Reports·Hannes PlanatscherNicole Schneiderhan-Marra
Apr 27, 2011·Clinical Transplantation·Maurício G SaueressigRedha Souilamas
Oct 16, 2015·Scientific Reports·Andreas OstermanMaria G Vizoso-Pinto
Dec 12, 2012·Diagnostic Microbiology and Infectious Disease·Sari M ViitalaAle Närvänen
Jan 9, 2019·Frontiers in Microbiology·Océane Sorel, Ilhem Messaoudi
Nov 6, 2021·Scientific Reports·Fernanda Raya-TonettiMaria Guadalupe Vizoso-Pinto
Oct 12, 2010·Archives of Biochemistry and Biophysics·Josefina M VillegasViviana A Rapisarda

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
gpELISA
ELISAs
PCR

Software Mentioned

recom Dot Scan
RecomLine
recomScan
Enzygnost

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.